AmCad BioMed Corporation
TTPEX:418817.15
TWD
+1.55
(+9.94%)
ISIN
TW0004188008
Return %
Stock
S&P 500
1Y
7.86
14.20
3Y
-13.21
81.12
5Y
-1.51
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Yi Li Lee
- Full Time Employees
- 69,576
- Sector
- Technology services
- Industry
- Packaged software
- Address
- No. 167 Fuxing North Road Taipei TP Taiwan 104
- IPO Date
- Oct 24, 2015
- Website
- amcad.com.tw
- Similar Companies
- Business
- AmCad BioMed Corporation (4188.TWO) develops and markets artificial intelligence-powered computer-aided detection and diagnosis (CAD) software devices for ultrasound imaging, primarily focused on early disease detection in endocrinology, hepatology, pulmonology, and oncology. The company offers a suite of FDA-cleared and CE-marked products, including AmCAD-UT Detection for analyzing ultrasound images of thyroid nodules to support thyroid cancer assessment; AmCAD-UO for non-invasive detection of obstructive sleep apnea via upper airway ultrasound scans; AmCAD-US for quantifying backscattered ultrasound signals to evaluate liver steatosis and fibrosis; AmCAD-UV for classifying and visualizing pulsatile signals from ultrasound data; AmCAD-CA for digital cytological image analysis in thyroid fine-needle aspiration; and AmCAD-UB for breast cancer detection in dense breast tissue. These solutions integrate with FDA-cleared ultrasound systems to provide real-time quantitative assessments, enhancing diagnostic accuracy for clinicians in hospitals, clinics, and outpatient settings. Founded in 2008 and headquartered at 5F, No. 167, Fuxing North Road, Zhongshan District, Taipei City, Taiwan, AmCad BioMed operates primarily in the medical devices segment of the healthcare industry, targeting physicians, radiologists, and ENT specialists worldwide with a focus on Asia, Europe, and North America. The company maintains a subsidiary relationship with Broadsound Corporation in Hsinchu, Taiwan, for research, development, and manufacturing support. In recent developments, AmCad BioMed expanded clinical validations for its AmCAD-UO system through collaborations with Bern University Hospital in Switzerland, resulting in a 2024 peer-reviewed publication in Otolaryngology–Head and Neck Surgery demonstrating its utility in predicting obstructive sleep apnea treatment outcomes; partnered with Stanford Sleep Center, with research results published in Sleep Medicine; and presented study findings at the International Surgical Sleep Society (ISSS) 2024 alongside Swiss clinicians. The company continues global market expansion, participating in major events such as RSNA 2025 in Chicago, MEDICA 2025 in Düsseldorf, and WHX Dubai 2026, while advancing real-time LIVE ultrasound AI modules for thyroid and breast indications. AmCad BioMed employs approximately 34-74 staff and upholds strong R&D commitments with multiple regulatory certifications, positioning it as a leader in ultrasound AI diagnostics.